Abstract: Objective:To analyze clinical characteristics, treatment, and prognosis of B-cell lymphoma, unclassifiable, with features in -termediate between diffuse large B-cell lymphoma and Burkitt lymphoma (DLBCL/BL). Methods:The clinical and pathological data of 13DLBCL/BL patients, who were treated in the First Affiliated Hospital of Zhengzhou University between January 2013and December 2014, were collected. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Through the log-rank test, survival curves were compared among groups classified by clinical stage, age, serum lactate dehydrogenase (LDH) lev -el, international prognostic index (IPI) score, or first chemotherapy regimen. Results: Among the 13patients with DLBCL/BL, 12pa-tients showed extra nodal involvement. The median OS and PFS were only 10and 6 months, respectively. Univariate analysis showed that the LDH levels and IPI scores exerted statistically significant effects on prognosis. Some borderline differences in survival were not -ed among the CHOP, CHOP- like, and intensive chemotherapy groups. Conclusion: DLBCL/BL is an aggressive B- cell lymphoma with a short survival time. The majority of patients presented extra-nodal involvement. DLBCL/BL did not respond well to CHOP or CHOP-like regimen, and more intensive chemotherapy may improve survival. Elevated LDH levels and high IPI scores were predictors of poor sur -vival.